Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Abbott Selling Developed Market Generics Portfolio

By BiotechDaily International staff writers
Posted on 29 Jul 2014
Abbott Laboratories (Abbot Park, IL, USA) has sold its developed market generic drugs business to Mylan (Canonsburg, PA, USA) in a deal worth USD 5.3 billion.

The sale to Mylan will be in the form of an equity ownership of a newly formed entity, to be named Mylan NV, in which Abbott will have a stake of 21%. The new entity will be based in the Netherlands to achieve tax savings. Mylan NV will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, which includes Europe, Japan, Canada, Australia, and New Zealand, as well as manufacturing facilities in France and Japan. The transaction will diversify Mylan's business and strengthen its commercial platform outside the US (the US sector is not included).

The assets, which are being acquired on a debt-free basis, include a portfolio of more than 100 specialty and branded generic pharmaceutical products in five major therapeutic areas—central nervous system/pain, cardio/metabolic, gastrointestinal, anti-infective/respiratory, and women's and men's health—and also includes several patent protected, novel, and hard-to-manufacture products with continued growth potential.

Abbott will retain its branded generics pharmaceuticals business and products in emerging markets, where demographics and growing healthcare systems are combining to create an increased rate of patient access to healthcare, and where the majority of healthcare products are paid for directly by the consumer. Abbott will also retain manufacturing facilities in emerging markets as well as those situated in the Netherlands, Germany, and Canada.

“This transaction provides Abbott with additional strategic flexibility as we continue to actively manage and shape our portfolio, reflecting our commitment to long-term, durable growth,” said Miles D. White, chairman and CEO of Abbott. “Our branded generics pharmaceuticals business will focus on emerging markets, where demographic changes and increasing access to healthcare are expected to drive sustainable growth.”

“We believe Mylan is uniquely positioned to realize improved financial performance and profitability from these assets by leveraging our integrated, efficient operating platform, more effectively distributing the portfolio across channels, and maintaining a greater strategic focus on key products,” said Heather Bresch, CEO of Mylan. “We have experience successfully integrating large, complex transactions such as this one, and we are confident in our ability to deliver the value inherent from this combination.”

Abbott does not expect to be a long-term shareholder in Mylan, and ultimately plans to redeploy the proceeds from the transaction to new opportunities in the devices and diagnostics sectors, with an emphasis on the diabetes, eye care, and vascular markets.

Related Links:

Abbott Laboratories
Mylan



SLAS - Society for Laboratory Automation and Screening
BIOSIGMA S.R.L.
RANDOX LABORATORIES
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: A 3-dimensional picture reveals how the antibodies in the experimental drug Zmapp bind to Ebola virus (Photo courtesy of the Scripps Research Institute).

Electron Microscope Imaging Shows How Experimental Anti-Ebola Drug Works

Electron microscope imaging has revealed how the experimental drug ZMapp binds to the Ebolavirus and provides insights into how the drug prevents growth of the pathogen. ZMapp, which was developed by... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.